News & Updates

Based on the EMA Guideline on Good Pharmacovigilance Practices (GVP) Chapter P.III – Product- or Population-Specific Considerations III

The Egyptian Drug Authority (EDA) has established a structured framework for managing variations to pharmaceutical products in the post-marketing phase. The document titled Administrative & Relevant Documents & Time frame for human pharmaceutical variations (Version 1/2026, Code NP. CAPP.109) serves as a critical guideline for applicants seeking to modify registered medicinal products.

New Zealand's Medsafe provides clear guidelines outlining the responsibilities and processes for ensuring participant safety during clinical investigations of both medicines and medical devices.

Every year on February 4th, the world unites under the banner of World Cancer Day. This global initiative, led by the Union for International Cancer Control (UICC), aims to raise awareness, improve education, and catalyze personal, collective, and government action to reimagine a world where millions of preventable cancer deaths are avoided and...

The State of Kuwait has established a robust and structured pharmacovigilance (PV) system, detailed comprehensively in the Kuwait Good Pharmacovigilance Practice (KuGVP) guidelines. This framework aligns Kuwait with international standards while addressing local regulatory needs, positioning the country as a committed guardian of patient safety.

Neglected Tropical Diseases (NTDs) remain a stark marker of global health inequity, affecting over 1.5 billion of the world's poorest and most marginalized people. The Global Report on Neglected Tropical Diseases 2025 by the World Health Organization (WHO) charts two decades of concerted action, revealing significant victories alongside persistent and emerging challenges.

The World Health Organization (WHO) released its Global Antibiotic Resistance Surveillance Report 2025, providing the most comprehensive analysis to date of antimicrobial resistance (AMR) worldwide. Based on data from the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS), the report covers over 23 million bacteriologically confirmed infections reported by 104 countries between 2016 and 2023.